readthroughSign in
Oct 15, 2026Weekly roundupUpdated

Sanofi registers new RSV immunization survey; three prior Queensland studies also update

A newly posted Australian observational study on nirsevimab immunization joins updates to Sanofi's chlamydia, cardiovascular flu, and combination vaccine survey records.

This week brought a new Sanofi-sponsored observational study alongside continued activity on three previously reported trials.

  • Sanofi completed a new observational study in Queensland, Australia, examining nirsevimab immunization rates among infants. The trial assessed immunisation rates among eligible infants born from 1 February 2024 to 15 April 2025 in their first Respiratory Syncytial Virus season in Queensland.1 The study is listed as completed, with 1113 participants enrolled1 and primary completion dated 2026-09-30.
  • Sanofi's chlamydia coding validation study with TriNetX US electronic health record data remains completed. The study examines whether TriNetX, a global health research network encompassing a worldwide electronic health record database in the US, is an appropriate real-world data source for conducting chlamydia-related research to support the chlamydia trachomatis mRNA vaccine program.2 The trial enrolled 4878935 participants2, with primary and study completion dated 2026-09-30.
  • VACC-UP (NCT07721649), led by Stephan Baldus with Sanofi as a collaborator, continues recruiting in Germany. The trial compares offering intrahospital influenza vaccination plus counseling against counseling alone in patients hospitalized for acute coronary syndrome or heart failure, with the primary endpoint being the influenza vaccination rate at the end of the index season (March 31)3. Planned enrollment is 482 participants (estimated)3.
  • A George Washington University survey study (NCT07871448), with Sanofi Pasteur as a collaborator, remains not yet recruiting. The study is designed to investigate healthcare worker attitudes around and willingness to receive combination influenza/COVID-19 vaccines4, with a quantitative phase intended to survey approximately 550 HCWs to characterize willingness to receive a combination influenza/COVID-19 vaccine and to identify demographic, attitudinal, and structural predictors of vaccination.4

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.